In Boston Business Journal Cover Story, Konstantin Linnik Comments on Microbiome DrugsPrint PDF
Konstantin Linnik, Ph.D., a partner in Nutter's Intellectual Property Department and Life Sciences practice group, weighed in on microbiome focused companies in a Boston Business Journal cover story on January 20. The article, “Gut-check time for Mass. biotechs: 'Is this the moment for microbiome drugs?',” discusses how new microbiome focused companies have attracted hundreds of millions of dollars in investments.
Konstantin notes that he has spoken with some funds that made early-stage investments in microbiome companies. "People who are early-stage investors are looking at transformative therapies," he said. "By changing the paradigm for treating infectious diseases, it could completely transform the way people are being treated today, and therefore it's a huge market opportunity.”